Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
IN8bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
INAB
Nasdaq
2836
in8bio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for IN8bio, Inc.
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
- Feb 11th, 2025 1:00 pm
IN8bio to Present at Biotech Showcase 2025 in San Francisco
- Jan 6th, 2025 12:00 pm
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
- Dec 10th, 2024 12:00 pm
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
- Dec 2nd, 2024 12:00 pm
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
- Nov 25th, 2024 12:00 pm
INAB: Upcoming Presentations at SNO & ASH
- Nov 14th, 2024 3:14 pm
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Nov 12th, 2024 9:26 pm
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
- Nov 12th, 2024 12:00 pm
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
- Nov 5th, 2024 2:00 pm
INAB: Restructuring Narrows Focus to AML
- Oct 2nd, 2024 11:18 am
IN8bio Announces Pricing of $12.4 Million Private Placement
- Oct 1st, 2024 12:00 pm
IN8bio cuts staff and pipeline to focus on AML cell therapy
- Sep 5th, 2024 12:33 pm
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
- Sep 4th, 2024 8:01 pm
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Aug 29th, 2024 10:05 am
INAB: AML & GBM Clinical Update
- Aug 14th, 2024 12:28 pm
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
- Aug 12th, 2024 12:05 pm
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Aug 8th, 2024 8:05 pm
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Jun 24th, 2024 12:00 pm
INAB: INB-100 Update at EHA24 ¡Olé!
- Jun 17th, 2024 9:40 am
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
- Jun 13th, 2024 8:01 pm
Scroll